Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925822 | 0.90 | CCR3 (0.62) | CCR3MCHR1 | |
| SCHEMBL2928190 | 0.77 | MCHR1 (0.57) | CCR3MCHR1PKM | |
| SCHEMBL9594285 | 0.72 | DRD4 (0.75) | CCR3MCHR1DRD4 | |
| SCHEMBL3149781 | 0.72 | CCR3 (0.72) | CCR3MCHR1DRD4 | |
| SCHEMBL20167961 | 0.70 | HRH3 (0.55) | ALDH1A1 | |
| SCHEMBL3134114 | 0.70 | MCHR1 (0.90) | CCR3MCHR1DRD4 | |
| SCHEMBL13177425 | 0.69 | MCHR1 (0.63) | MCHR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL678150 | 0.69 | MCHR1 (1.00) | MCHR1DRD4 | |
| SCHEMBL2536771 | 0.69 | NPC1 (0.64) | KMT2AMEN1 | |
| SCHEMBL9872559 | 0.69 | DRD4 (0.78) | CCR3MCHR1DRD4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | CCR3 1149/4885MCHR1 1/4885DRD4 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.